Sign In
Buy BCAB
$3.29
-0.0900 (-2.66%)
At Close: Jul 31, 2026
BioAtla (NASDAQ:BCAB) Trading 12.4% Higher – Should You Buy?
03:00am, Wednesday, 22'nd Oct 2025
Shares of BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) traded up 12.4% during mid-day trading on Tuesday. The company traded as high as $0.70 and last traded at $0.69. 1,570,186 shares were traded d
Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS) Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cP
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
09:00am, Friday, 03'rd Oct 2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval Company continues preparations for enabling initiatio
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval Company continues preparations for enabling initiatio
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
02:43am, Saturday, 09'th Aug 2025
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Participants Eric L. Sievers - Chief Medical Officer Jay M.
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
01:05pm, Thursday, 07'th Aug 2025
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
08:00am, Monday, 04'th Aug 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
05:00am, Monday, 04'th Aug 2025
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
08:00am, Thursday, 17'th Jul 2025
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionall
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
05:00am, Thursday, 17'th Jul 2025
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionall
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
08:00am, Thursday, 03'rd Jul 2025
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients D
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
05:00am, Thursday, 03'rd Jul 2025
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients D
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; stan
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
05:55pm, Tuesday, 06'th May 2025
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Offi
